Literature DB >> 23055903

A New Kid on the Block: IL-10+ Regulatory B Cells and a Possible Role In Psoriasis.

Kamruz Darabi1, Rohit Jaiswal, Sarah G Hostetler, Mark A Bechtel, Matthew J Zirwas, Patricia Witman.   

Abstract

The pivotal role of T cells in the etiology of psoriasis has been elucidated; however, the mechanisms that regulate these T cells are unclear. Recently, it has been shown that an IL-10 producing B cell population may downregulate T cell function and it has been hypothesized that depletion of this B cell population may lead to exacerbation of T-cell mediated autoimmune disease. We present the case of an adolescent male with autoimmune lymphoproliferative syndrome (ALPS) being treated with the anti-CD20 chimeric monoclonal antibody rituximab in addition to intravenous immune globulin (IVIG) for immune thrombocytopenia (ITP) who developed a psoriasiform rash on his hands following mechanical trauma with concomitant severely decreased B cell count. We propose that depletion of the patient's B cells due to rituximab treatment may have led to abrogation of IL-10+ B-cell regulation of T cells. The development of a psoriasiform rash in this predisposed individual may have been triggered by mechanical trauma to his hands (koebnerization). In addition, we believe the patient's rash may have been tempered by concomitant treatment with IVIG, which has been used as treatment in cases of psoriasis. We discuss the immunologic mechanism of psoriasis and the role that a recently described IL-10+ B cell may play in preventing the pathologic process. Further studies are needed to more clearly elucidate this process.

Entities:  

Keywords:  ALPS; IL-10; IVIG; psoriasiform; rituximab

Year:  2009        PMID: 23055903      PMCID: PMC3461942          DOI: 10.5863/1551-6776-14.3.148

Source DB:  PubMed          Journal:  J Pediatr Pharmacol Ther        ISSN: 1551-6776


  15 in total

Review 1.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin.

Authors:  M D Kazatchkine; S V Kaveri
Journal:  N Engl J Med       Date:  2001-09-06       Impact factor: 91.245

Review 2.  B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.

Authors:  T Shaw; J Quan; M C Totoritis
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

Review 3.  Fcgamma receptors as regulators of immune responses.

Authors:  Falk Nimmerjahn; Jeffrey V Ravetch
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

4.  Development of psoriasis after B cell depletion with rituximab.

Authors:  Shouvik Dass; Edward M Vital; Paul Emery
Journal:  Arthritis Rheum       Date:  2007-08

Review 5.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 6.  Pathogenesis and therapy of psoriasis.

Authors:  Michelle A Lowes; Anne M Bowcock; James G Krueger
Journal:  Nature       Date:  2007-02-22       Impact factor: 49.962

Review 7.  Psoriasis, T cells and autoimmunity.

Authors:  C E Griffiths; J J Voorhees
Journal:  J R Soc Med       Date:  1996-06       Impact factor: 18.000

Review 8.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance.

Authors:  Mitchell R Smith
Journal:  Oncogene       Date:  2003-10-20       Impact factor: 9.867

Review 9.  Not always the bad guys: B cells as regulators of autoimmune pathology.

Authors:  Simon Fillatreau; David Gray; Stephen M Anderton
Journal:  Nat Rev Immunol       Date:  2008-05       Impact factor: 53.106

10.  Rituximab responsive immune thrombocytopenic purpura in an adult with underlying autoimmune lymphoproliferative syndrome due to a splice-site mutation (IVS7+2 T>C) affecting the Fas gene.

Authors:  Andrew Wei; Tiffany Cowie
Journal:  Eur J Haematol       Date:  2007-08-28       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.